Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company focused on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company's mission is to eradicate these diseases, with a particular emphasis on Rett syndrome, a rare and devastating neurodevelopmental disorder. Taysha employs a disciplined approach, focusing on its most promising therapeutic candidates and leveraging a clinically and commercially proven adeno-associated virus serotype 9 (AAV9) capsid, intrathecal delivery, and efficient manufacturing processes.

Taysha's team is comprised of experts with a strong track record in gene therapy and rare diseases, having been responsible for the development and commercialization of the first U.S. FDA approved gene therapy to treat a monogenic CNS disorder. The company is actively pursuing clinical trials for its lead candidate, TSHA-102, for Rett syndrome, and has secured regulatory designations like RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Taysha is committed to working closely with patients, caregivers, and advocacy organizations to ensure that its research and development efforts benefit the rare disease community.

Taysha Gene Therapies offers flexible work arrangements for some positions, with both the Associate Director, Regulatory Affairs Project Manager and Vice President, Clinical Development roles being advertised as remote. While the company's website does not explicitly mention a general policy on remote work, these job postings indicate a willingness to consider remote candidates for specific roles.

Taysha Gene Therapies is dedicated to eradicating monogenic diseases of the central nervous system (CNS). They are focused on discovering, developing, and commercializing gene therapies for both rare and large patient populations, with a particular emphasis on Rett syndrome. Their mission is driven by the belief that gene therapy can dramatically improve the lives of patients living with CNS diseases caused by a single gene mutation, providing hope and a chance for a better future.

Taysha Gene Therapies fosters a collaborative and patient-centric culture, emphasizing teamwork, integrity, accountability, and a relentless focus on delivering transformative treatments for those living with devastating central nervous system diseases. Their shared passion and drive are rooted in their mission to eradicate monogenic CNS diseases, driving them to explore uncharted territory, uncover groundbreaking scientific discoveries, and develop cutting-edge technologies and medicines. This commitment to innovation and making a real difference in the lives of patients and families defines their culture.